About: Comparing the Cobas Liat Influenza A/B and respiratory syncytial virus assay with multiplex nucleic acid testing

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Comparing the Cobas Liat Influenza A/B and respiratory syncytial virus assay with multiplex nucleic acid testing Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Comparing the Cobas Liat Influenza A/B and respiratory syncytial virus assay with multiplex nucleic acid testing
Creator	Hirsch, Hans Gosert, Rainer Klaudia Naegele, \|
Source	Medline; PMC
abstract	Influenza virus and respiratory syncytial virus (RSV) detection with short turn‐around‐time (TAT) is pivotal for rapid decisions regarding treatment and infection control. However, negative rapid testing results may come from poor assay sensitivity or from influenza‐like illnesses caused by other community‐acquired respiratory viruses (CARVs). We prospectively compared the performance of Cobas Liat Influenza A/B and RSV assay (LIAT) with our routine multiplexNAT‐1 (xTAG Respiratory Pathogen Panel; Luminex) and multiplexNAT‐2 (ePlex‐RPP; GenMark Diagnostics) using 194 consecutive nasopharyngeal swabs from patients with influenza‐like illness during winter 2017/2018. Discordant results were reanalyzed by specific in‐house quantitative nucleic acid amplification testing (NAT). LIAT was positive for influenza virus‐A, ‐B, and RSV in 18 (9.3%), 13 (6.7%), and 55 (28.4%) samples, and negative in 108 samples. Other CARVs were detected by multiplexNAT in 66 (34.0%) samples. Concordant results for influenza and RSV were seen in 190 (97.9%), discordant results in 4 (2.1%), which showed low‐level RSV (<40 000 copies/mL). Sensitivity and specificity of LIAT for influenza‐A, ‐B, and RSV were 100%, 100% and 100%, and 100%, 99.5% and 100%, respectively. The average TAT of LIAT was 20 minutes compared to 6 hours and 2 hours for the multiplexNAT‐1 and ‐2, respectively. Thus, LIAT demonstrated excellent sensitivity and specificity for influenza and RSV, which together with the simple sample processing and short TAT renders this assay suitable for near‐patient testing.
has issue date	2018-11-13(xsd:dateTime)
bibo:doi	10.1002/jmv.25344
bibo:pmid	30345524
has license	no-cc
sha1sum (hex)	50ca0f1de477a68ad2e62202b32a4c84125836cc
schema:url	https://doi.org/10.1002/jmv.25344
resource representing a document's title	Comparing the Cobas Liat Influenza A/B and respiratory syncytial virus assay with multiplex nucleic acid testing
has PubMed Central identifier	PMC7166997
has PubMed identifier	30345524
schema:publication	J Med Virol
resource representing a document's body	covid:50ca0f1de477a68ad2e62202b32a4c84125836cc#body_text
is schema:about of	named entity 'pivotal' named entity 'Influenza A' named entity 'LIAT' named entity 'performance' named entity 'influenza' named entity 'assay' named entity 'respiratory syncytial virus' named entity 'RSV' named entity 'viruses' named entity 'influenza virus' named entity 'RSV' named entity 'assay' named entity 'nucleic acid testing' named entity 'viruses' named entity 'pathogens' named entity 'submersed' named entity 'RSV' named entity 'influenza' named entity 'pipette' named entity 'immunocompromised patients' named entity 'RSV' named entity 'influenza virus' named entity 'RSV' named entity 'viruses' named entity 'plasmid' named entity 'RSV' named entity 'plasmid' named entity 'matrix protein' named entity 'pathogens' named entity 'standard curve' named entity 'influenza virus' named entity 'cell culture' named entity 'influenza virus' named entity 'infection control' named entity 'human metapneumovirus' named entity 'cell culture' named entity 'influenza virus' named entity 'influenza-like' named entity 'pathogens' named entity 'viral load' named entity 'quality assurance' named entity 'parainfluenza' named entity 'short turn' named entity 'infection control' named entity 'influenza virus' named entity 'influenza virus' named entity 'quality assurance programs' named entity 'antigen' named entity 'RSV' named entity 'statistical significance' named entity 'influenza virus' named entity 'RSV' named entity 'gold standard' named entity 'VTM' named entity 'genome' named entity 'RSV' named entity 'influenza virus' named entity 'assay' named entity 'RSV' named entity 'VTM' named entity 'RSV' named entity 'infection control' named entity 'Influenza virus' named entity 'RSV' named entity 'pathogen' named entity 'antiviral therapy' named entity 'pathogen' named entity 'enterovirus' named entity 'influenza virus' named entity 'influenza' named entity 'quality assurance' named entity 'RSV' named entity 'morbidity' named entity 'sensitive and specific' named entity 'VTM' named entity 'nonstructural protein' named entity 'pathogens' named entity 'hospital settings' named entity 'virus isolation'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software